LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

39.68 3.55

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

37.61

Max

39.81

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Peļņas marža	-1,582.642
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+5.45% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.8B 5.9B
Iepriekšējā atvēršanas cena	36.13
Iepriekšējā slēgšanas cena	39.68

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 25. nov. 16:56 UTC

Peļņas

Galvenie tirgus virzītāji

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

2025. g. 25. nov. 23:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 25. nov. 23:47 UTC

Tirgus saruna

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

2025. g. 25. nov. 22:39 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 25. nov. 22:39 UTC

Tirgus saruna

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

2025. g. 25. nov. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 25. nov. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 25. nov. 21:38 UTC

Peļņas

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

2025. g. 25. nov. 21:31 UTC

Tirgus saruna

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

2025. g. 25. nov. 21:27 UTC

Peļņas

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

2025. g. 25. nov. 21:20 UTC

Peļņas

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

2025. g. 25. nov. 21:18 UTC

Peļņas

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

2025. g. 25. nov. 21:15 UTC

Peļņas

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

2025. g. 25. nov. 20:16 UTC

Tirgus saruna

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

2025. g. 25. nov. 18:42 UTC

Tirgus saruna

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

2025. g. 25. nov. 18:25 UTC

Iegādes, apvienošanās, pārņemšana

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

2025. g. 25. nov. 17:30 UTC

Tirgus saruna

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

2025. g. 25. nov. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 25. nov. 17:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 25. nov. 16:33 UTC

Iegādes, apvienošanās, pārņemšana

Eni: Financial Details Weren't Disclosed

2025. g. 25. nov. 16:33 UTC

Iegādes, apvienošanās, pārņemšana

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

2025. g. 25. nov. 16:32 UTC

Iegādes, apvienošanās, pārņemšana

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

2025. g. 25. nov. 16:31 UTC

Iegādes, apvienošanās, pārņemšana

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

2025. g. 25. nov. 16:30 UTC

Iegādes, apvienošanās, pārņemšana

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

2025. g. 25. nov. 16:23 UTC

Peļņas

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

2025. g. 25. nov. 16:12 UTC

Tirgus saruna

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

2025. g. 25. nov. 16:11 UTC

Tirgus saruna

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

2025. g. 25. nov. 16:10 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 25. nov. 16:10 UTC

Tirgus saruna

Sterling Could Briefly Rise After Budget -- Market Talk

2025. g. 25. nov. 16:10 UTC

Tirgus saruna

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

5.45% augšup

Prognoze 12 mēnešiem

Vidējais 40.64 USD 5.45%

Augstākais 65 USD

Zemākais 20 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.